Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003311 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00003311: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00003311 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003311, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients with newly diagnosed mantle cell lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 1998-05-20 |
| Est. Completion | 2007-04-18 |
| Phase | Phase 2 |
What the finished NCT00003311 record still lists
NCT00003311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003311 about?
NCT00003311 is a clinical study titled "Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients...
What is the current status of trial NCT00003311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 1998-05-20. Estimated completion is 2007-04-18.
What interventions are being tested in trial NCT00003311?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00003311?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003311's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI